Why involve payers now?

At this stage, payer input becomes more focused on refining study design and evidence generation to support reimbursement decisions.

• As a new treatment moves closer to protocol finalization, early payer involvement becomes increasingly important to shaping a compelling, credible value story. The synopsis phase is the opportunity to align study design with payer priorities-ensuring continued interest, relevance, and downstream access success.
• Engaging payers at this stage helps by articulating its clinical and economic value, including improvements in health outcomes, quality of life, and cost-effectiveness. Incorporating comparative data, where feasible, further reinforces differentiation from existing options.
• Payers can also provide insight into how health economic models may be structured to illustrate budget impact and long-term cost savings, supporting informed coverage decisions. Emphasizing patient centered outcomes, such as patient reported outcomes and quality of life measures, aligns the study with evidence that increasingly influences payer decision making.
• Finally, ensuring trial design and data collection approaches align with regulatory expectations enhances credibility, while tailoring communication to payer decision frameworks maximizes the impact and usability of study results.